Avapro, Hyzaar Paragraph IV Filings
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Merck's antihypertensive agent Hyzaar (losartan/ hydrochlorothiazide) was filed May 24, according to FDA's July 15 updated list of Paragraph IV filings
You may also be interested in...
Cozaar Paragraph IV Certification
FDA's Feb. 2 updated list of first-time Paragraph IV certifications reflects a filing for Merck's angiotensin II inhibitor Cozaar (losartan)
Cozaar Paragraph IV Certification
FDA's Feb. 2 updated list of first-time Paragraph IV certifications reflects a filing for Merck's angiotensin II inhibitor Cozaar (losartan)
Merck's Hyzaar Adds Front-Line Severe Hypertension Indication
The antihypertensive was previously indicated for initial use only when hypertension was severe enough that the value of promptly controlling blood pressure exceeded the risk of therapy with the losartan/hydrochlorothiazide combination.